NCT06176534招募中2 期
Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 240
- 试验地点
- 1
- 主要终点
- ORR by investigator using RECIST Guideline (Version 1.1)
研究概览
简要总结
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.
详细描述
To observe the differences in the efficacy of Combination followed by maintenance chemotherapy versus CDK4/6 inhibitor combined with endocrine therapy in HR low expression /HER2 negative advanced breast cancer, and to provide new evidence for the best treatment of HR low expression /HER2 negative advanced breast cancer, and to explore the efficacy and safety of combined/maintenance chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •age ≥18 years old; Invasive breast cancer with metastatic disease confirmed by histological or cytological examination; Patients without pathologically or cytologically confirmed metastatic disease should have clear evidence of metastasis by physical examination or radiological studies;
- •The most recent pathological report of biopsy confirmed HR low expression and HER2 negative.
- •HR low expression was defined as 1-50% ER expression by immunohistochemistry (IHC); Or ER<1% and PR≥1%; Patients with ER expression of 1-10% or ER-/ PR-positive patients were eligible for inclusion after careful evaluation by the investigator, and those with a small tumor burden and candidates for endocrine therapy were eligible.
- •HER2-negative definition: IHC 0 or 1+; If the IHC was 2+, it was confirmed negative by fluorescence in situ hybridization (FISH).
- •at least one measurable lesion;
- •No previous salvage chemotherapy for metastatic disease was required, and first-line endocrine therapy was allowed;
- •no previous CDK4/6 inhibitor; For adjuvant CDK4/6i treatment, recurrence and metastasis were required more than 1 year after drug withdrawal.
- •Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1, life expectancy is more than 12 weeks;
- •Adequate function of major organs.
- •All adverse events recovered to grade 1 or less before enrollment (NCI CTCAE version 5.0);
- •patients without major organ dysfunction and heart disease;
- •Women and men of childbearing potential must agree to use appropriate contraception before and during study participation.
排除标准
- •symptomatic, uncontrolled brain or leptomeningeal metastases; Patients who had received previous systemic radical treatment for brain metastases (radiotherapy or surgery), if stable disease had been maintained for at least 1 month as confirmed by imaging, and if systemic hormone therapy (dose 10mg/ day prednisone or other effective hormones) for more than 2 weeks without clinical symptoms.
- •patients received radiotherapy, chemotherapy, major surgery, targeted therapy or immunotherapy within 2 weeks before enrollment; Patients received endocrine therapy within 1 week before enrollment. Chemotherapy with nitrosourea or mitomycin was administered within 6 weeks before enrollment.
- •participated in other clinical trials of new drugs within 4 weeks before enrollment;
- •there can not be controlled by drainage or pneumatic methods third space effusion;
- •patients with other malignant tumors within the past 3 years, excluding radical cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma;
- •suffering from serious or uncontrolled diseases, including but not limited to: 1) active viral infection, such as HIV or HBV active (HbsAg positive and HBV-DNA≥103, hepatitis C antibody positive); 2) history of severe cardiovascular disease: uncontrolled hypertension; Myocardial infarction, unstable arrhythmia, congestive heart failure, pericarditis, myocarditis, etc. Patients with NYHA class ⅲ-ⅳ cardiac dysfunction, or left ventricular ejection fraction (LVEF) 50% by echocardiography; 3) severe infection (e.g., intravenous antibiotic, antifungal, or antiviral therapy according to clinical practice) within 4 weeks prior to the first dose or unexplained fever during screening/before the first dose; 38.3°C (fever due to cancer, as judged by the investigator, was eligible);
- •patients with a history of psychotropic drug abuse and unable to abstain or with mental disorders; Or accompanied by swallowing and absorption dysfunction;
- •patients with other concomitant diseases that seriously endanger the safety of patients or affect the completion of the study according to the judgment of the investigators;
- •patients with known history of allergy to the components of this regimen; A history of immunodeficiency, including testing positive for HIV, HCV or other acquired or congenital immunodeficiency disorders, or a history of organ transplantation;
- •pregnant or lactating women;
- •Patients deemed unsuitable for inclusion by the investigators.
结局指标
主要结局
ORR by investigator using RECIST Guideline (Version 1.1)
时间窗: 6 weeks
ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR assessed by the investigator according to RECIST version 1.1
次要结局
- Adverse events(up to 1.5 years)
- PFS(up to 1.5 years)
- OS(up to 3 years)
研究者
Min Yan, MD
Chief Physician
Henan Cancer Hospital
研究点 (1)
Loading locations...
相似试验
已完成
3 期
A phase III randomized study with Paclitaxel (Taxol) and Gemcitabine or Vinorelbine in patients with stage IIIBw - IV non-operable non-small cell lung cancer (NSCLC), performance status (PS) 0,1.Non-Small Cell Lung CancerACTRN12609000946213Hellenic Cooperative Oncology Group441
尚未招募
2 期
Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal CancerMetastatic Colorectal CancerRadiotherapyNCT03142282Wuhan Union Hospital, China200
已完成
3 期
Chemotherapy Options for the First Line Chemotherapy in Elderly Patient With Advanced Gastric CancerGastric CancerNCT02114359Seoul National University Hospital111
进行中（未招募）
2 期
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung CancerNCT03137771NRG Oncology218
已完成
不适用
Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line ChemotherapyMetastatic Breast CancerNCT04258163Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University760